Unraveling the multifaceted insights into amyotrophic lateral sclerosis: Genetic underpinnings, pathogenesis, and therapeutic horizons
- PMID: 39491718
- DOI: 10.1016/j.mrrev.2024.108518
Unraveling the multifaceted insights into amyotrophic lateral sclerosis: Genetic underpinnings, pathogenesis, and therapeutic horizons
Abstract
Amyotrophic Lateral Sclerosis (ALS), a progressive neurodegenerative disease, primarily impairs upper and lower motor neurons, leading to debilitating motor dysfunction and eventually respiratory failure, widely known as Lou Gehrig's disease. ALS presents with diverse symptomatology, including dysarthria, dysphagia, muscle atrophy, and hyperreflexia. The prevalence of ALS varies globally, with incidence rates ranging from 1.5 to 3.8 per 100,000 individuals, significantly affecting populations aged 45-80. A complex interplay of genetic and environmental factors underpins ALS pathogenesis. Key genetic contributors include mutations in chromosome 9 open reading frame 72 (C9ORF72), superoxide dismutase type 1 (SOD1), Fusedin sarcoma (FUS), and TAR DNA-binding protein (TARDBP) genes, accounting for a considerable fraction of both familial (fALS) and sporadic (sALS) cases. The disease mechanism encompasses aberrant protein folding, mitochondrial dysfunction, oxidative stress, excitotoxicity, and neuroinflammation, contributing to neuronal death. This review consolidates current insights into ALS's multifaceted etiology, highlighting the roles of environmental exposures (e.g., toxins, heavy metals) and their interaction with genetic predispositions. We emphasize the polygenic nature of ALS, where multiple genetic variations cumulatively influence disease susceptibility and progression. This aspect underscores the challenges in ALS diagnosis, which currently lacks specific biomarkers and relies on symptomatology and familial history. Therapeutic strategies for ALS, still in nascent stages, involve symptomatic management and experimental approaches targeting molecular pathways implicated in ALS pathology. Gene therapy, focusing on specific ALS mutations, and stem cell therapy emerge as promising avenues. However, effective treatments remain elusive, necessitating a deeper understanding of ALS's genetic architecture and the development of targeted therapies based on personalized medicine principles. This review aims to provide a comprehensive understanding of ALS, encouraging further research into its complex genetic underpinnings and the development of innovative, effective treatment modalities.
Keywords: Amyotrophic lateral sclerosis; Gene therapy; Genetic mutations (C9ORF72, SOD1, FUS, TDP-43); Motor neuron degeneration; Neuroinflammation; Polygenic etiology.
Copyright © 2024 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Genetic epidemiology of amyotrophic lateral sclerosis in Cyprus: a population-based study.Sci Rep. 2024 Dec 28;14(1):30781. doi: 10.1038/s41598-024-80851-y. Sci Rep. 2024. PMID: 39730482 Free PMC article.
-
Amyotrophic lateral sclerosis with SOD1 mutations shows distinct brain metabolic changes.Eur J Nucl Med Mol Imaging. 2022 Jun;49(7):2242-2250. doi: 10.1007/s00259-021-05668-7. Epub 2022 Jan 25. Eur J Nucl Med Mol Imaging. 2022. PMID: 35076740 Free PMC article.
-
Upregulated miR-10b-5p as a potential miRNA signature in amyotrophic lateral sclerosis patients.Front Cell Neurosci. 2024 Nov 7;18:1457704. doi: 10.3389/fncel.2024.1457704. eCollection 2024. Front Cell Neurosci. 2024. PMID: 39588282 Free PMC article.
-
Pathological mechanisms underlying TDP-43 driven neurodegeneration in FTLD-ALS spectrum disorders.Hum Mol Genet. 2013 Oct 15;22(R1):R77-87. doi: 10.1093/hmg/ddt349. Epub 2013 Jul 29. Hum Mol Genet. 2013. PMID: 23900071 Free PMC article. Review.
-
Depressing time: Waiting, melancholia, and the psychoanalytic practice of care.In: Kirtsoglou E, Simpson B, editors. The Time of Anthropology: Studies of Contemporary Chronopolitics. Abingdon: Routledge; 2020. Chapter 5. In: Kirtsoglou E, Simpson B, editors. The Time of Anthropology: Studies of Contemporary Chronopolitics. Abingdon: Routledge; 2020. Chapter 5. PMID: 36137063 Free Books & Documents. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous